USANA Health Sciences, Inc. — Form 10-Q Summary
Period: The filing covers the quarter ended March 30, 2024, compared with the quarter ended April 1, 2023. This differs from the request metadata’s “2023 Q1.” Amounts below are in U.S. dollars; financial statement amounts are converted from thousands to millions where shown.
Business context and results
USANA develops and manufactures nutrition, personal care, and skincare products, distributed primarily through direct selling. It reported approximately 494,000 active customers, up 0.6% year over year. Sales outside the United States represented 90.3% of consolidated net sales.
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Net sales | $227.8 million | $248.4 million | Down 8.3% |
| Gross profit | $184.7 million | $199.8 million | Down 7.6% |
| Gross margin | 81.1% | 80.5% | Up 0.6 percentage points |
| Operating earnings | $24.7 million | $26.8 million | Down 8.1% |
| Net earnings | $16.5 million | $18.4 million | Down 10.0% |
| Diluted EPS | $0.86 | $0.95 | Down 9.5% |
| Operating cash flow | $17.7 million | $12.8 million | Up $4.9 million |
Revenue drivers and material changes
- Management attributed the sales decline primarily to lower average customer spending, partly offset by a slight increase in active customers and modest price increases. Unfavorable currency movements reduced sales by an estimated $7.2 million; sales declined 5.4% excluding currency effects.
- Greater China sales increased 3.1% to $127.6 million (up 7.4% excluding currency effects), supported by higher customer counts and a market-specific incentive promotion. Southeast Asia Pacific sales fell 22.1% to $36.1 million, and North Asia fell 27.7% to $21.4 million. Americas and Europe sales fell 12.2% to $42.7 million.
- Gross margin improved through favorable market and product mix, lower inventory scrap charges, and price increases, partly offset by currency. Associate incentives declined to 42.0% of sales from 42.7%; selling, general and administrative expense declined in dollars but rose as a proportion of sales due to lower revenue.
- The effective tax rate rose to 39.0% from 35.5%, primarily because of the mix of pretax income by market. Management also cited elevated Q1 2023 China demand following a change in COVID-19 policy and customer purchases ahead of prior-year price increases as comparisons affecting the year-over-year result.
Cash, debt, and liquidity
- Cash and cash equivalents were $328.3 million at March 30, 2024, versus $330.4 million at December 30, 2023. Cash, cash equivalents, and restricted cash totaled $331.1 million.
- Operating activities provided $17.7 million; investing activities used $4.1 million, including $3.2 million of property and equipment purchases; financing activities used $11.9 million, including $9.4 million for share repurchases and $3.0 million for equity-award tax withholding.
- No borrowings were outstanding under the $75 million revolving credit facility. Local lines of credit totaled $1.32 million, compared with $0.79 million at year-end. The facility matures in August 2025 and includes quarterly EBITDA and leverage covenants. Management said current cash, expected operating cash flow, and available credit should cover ordinary-course needs for the foreseeable future.
- The company repurchased 194,000 shares for approximately $9.5 million during the quarter; $61.7 million remained authorized for repurchases.
Outlook, risks, and other notable items
- The filing provides no numerical revenue or earnings guidance. Management noted that adverse operating conditions or unusual capital needs could require additional financing, which may not be available on favorable terms.
- Key disclosed risks include dependence on direct selling and Associate activity; regulation of direct selling, especially in China; foreign-exchange volatility; macroeconomic and consumer-spending conditions; supply-chain and raw-material disruptions; data privacy and cybersecurity; geopolitical developments; and compliance with credit covenants.
- Cash transfers from China to the United States are delayed by Chinese accounting and tax requirements; future regulatory changes could further limit remittances.
- Management reported that disclosure controls were not effective at quarter-end because of material weaknesses in IT general controls. Remediation is ongoing, including added ITGC expertise, training, and third-party consulting; management expects remediation before fiscal year-end 2024, subject to testing. The filing reports no material change to the risk factors from the 2023 Form 10-K.
- The company is involved in ordinary-course legal matters. Management does not currently expect them, individually or collectively, to materially adversely affect financial condition, liquidity, or results, but some reasonably possible contingencies cannot currently be estimated.
Important facts for investors to verify
- Confirm the intended reporting period: the supplied filing is for Q1 2024, not Q1 2023.
- Track customer counts, average customer spending, and sales trends in Greater China versus declines in Southeast Asia Pacific, North Asia, and the Americas and Europe.
- Assess whether margin improvements can persist if sales remain weak, and monitor currency impacts and the effective tax rate.
- Review progress and testing of ITGC remediation, particularly given management’s conclusion that disclosure controls were ineffective.
- Monitor China remittance constraints, credit-facility covenant compliance, and the company’s use of cash for repurchases and other capital needs.